Drug Trial Radar · NCT07620041
Phase I Study of QLC5508 in Advanced Solid Tumors: C-QTc, Pharmacokinetics (PK) Comparisons and Drug-drug Interaction
Last checked: Nov 19, 2026Latest source record: Sep 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
48
Planned (sponsor's estimate)
Start
Jun 9, 2026
Primary completion
Dec 5, 2026
Study completion Feb 5, 2027
Sponsor
- Lead sponsor
- Qilu Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jun 2, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A clinical trial of QLC5508 for advanced solid tumors The goal of this clinical trial is to learn if QLC5508 can be given safely to adults with advanced solid tumors. It will also learn how two different formulations of QLC5508 compare in the body, and whether other drugs affect QLC5508. The main questions it aims to answer are: Does a single injection of QLC5508 change the heart's electrical activity (QTc interval)? How do the test formulation and the reference formulation of QLC5508 compare in the body (pharmacokinetics)? Do other drugs (itraconazole, darolutamide, or rifampicin) change how the body processes QLC5508? Investigators will compare the test formulation to the reference formulation, and will also give QLC5508 together with itraconazole, darolutamide, or rifampicin to look for drug-drug interactions. Participants will: Receive QLC5508 by injection into a vein; Join one of three groups: two groups will receive both formulations of QLC5508 at different times (crossover) and also take rifampicin or itraconazole; the third group will take darolutamide with QLC5508; Have heart monitoring (Holter) during the first dose; Undergo regular blood tests, safety checks, and immunogenicity testing (to see if the body develops antibodies against QLC5508).
Conditions
- Refractory or Relapsed Solid Tumors
Interventions
QLC5508 (Investigational Product / Formulation T)Drug
Single intravenous (IV) infusion of QLC5508 for pharmacokinetic (PK) and C-QTc assessment in patients with advanced solid tumors.
QLC5508 (Reference Product / Formulation R)Drug
Single IV infusion of QLC5508 for comparative PK evaluation against the investigational formulation.
ItraconazoleDrug
Multiple oral doses of itraconazole capsules to evaluate the drug-drug interaction (DDI) potential via CYP3A4 inhibition.
DarolutamideDrug
Multiple oral doses of darolutamide tablets to evaluate the drug-drug interaction (DDI) potential.
RifampicinDrug
Single oral dose of rifampicin capsules to evaluate the DDI potential.
Primary outcomes
What the sponsor says the trial is designed to measure.
- The correlation between the plasma concentration of the QLC5508 payload and the change from baseline in the QTc interval (ΔQTc) derived from the concentration-QTc (C-QTc) model.Time frame: Time Frame: From baseline to approximately Month 6
- Following a single intravenous injection of QLC5508 Formulation T (investigational product) versus Formulation R (reference product), the Cmax of QLC5508Time frame: From baseline to approximately Month 6
- TheAUC0-t of QLC5508 following single use or co-administration with itraconazoleTime frame: From baseline to approximately Month 6
- The AUC0-∞ of QLC5508 following single use or co-administration with darolutamideTime frame: From baseline to approximately Month 6
- The Tmax of QLC5508 following single use or co-administration with rifampicinTime frame: From baseline to approximately Month 6
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Jilin Province Tumor Hospital
Changchun, Jilin, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.